Skip to content

Annexon ANNX Investing Cash Flow

Investing Cash Flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$428.9M-166%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$133.97M-1,006%
Omeros logo
OmerosOMER
$28.73M-25.4%
Vor Biopharma logo
Vor BiopharmaVOR
-$263.24M-114,351%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$32.41M-11.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$350.79M-903%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's investing cash flow?
Annexon (ANNX) reported investing cash flow of $27.06M in Q1 2026.
How has Annexon's investing cash flow changed year-over-year?
Annexon's investing cash flow decreased by 72.3% year-over-year, from $97.62M to $27.06M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.